Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
about
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance studyComparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults.Hidden epidemic of macrolide-resistant pneumococci.The Binax NOW test as a tool for diagnosis of severe acute otitis media and associated complications.Molecular characterization and evaluation of the emerging antibiotic-resistant Streptococcus pyogenes from eastern India.Global fluoroquinolone resistance epidemiology and implictions for clinical use.The efficacy of cefdinir in acute bacterial rhinosinusitis.Acute bacterial rhinosinusitis: a review of U.S. treatment guidelines.Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumoniaImpact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.Comparison of BD phoenix to vitek 2, microscan MICroSTREP, and Etest for antimicrobial susceptibility testing of Streptococcus pneumoniae.Antibiotics in acute exacerbations of chronic bronchitis.Levofloxacin in the treatment of community-acquired pneumonia.Levofloxacin for the treatment of respiratory tract infections.Ketolides in the treatment of community-acquired respiratory tract infections: A review.Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapyAntimicrobial susceptibility trends among Streptococcus pneumoniae over an 11-year period in an Iranian referral children Hospital.Antimicrobial susceptibility of invasive and lower respiratory tract isolates of Streptococcus pneumoniae, 1998 to 2007.Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations.Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004.Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits.Bacteriological findings and antimicrobial susceptibility in chronic sinusitis with nasal polyp.
P2860
Q24682283-44A9FCFE-412B-471C-BA41-9D518510560EQ34589503-C0D48486-5773-4272-8556-437D656FE13BQ34596526-2AABBBD2-B235-4D16-B2F8-74F030140F18Q36009405-14843C88-BFAA-40DD-9704-41B23A0B7489Q36098637-47D1E319-6E32-4781-8098-9737D2BD3E5AQ36220784-BFBC58D2-0D09-4B64-9AD9-2E95FFA3EEDEQ36337074-FD0DAAA8-051F-4487-A5EE-5ED04DF53202Q36488221-00665E46-A683-4221-83FC-C89A44ADE56DQ36584323-86176D97-9CAE-4C80-B45F-9150E78726C2Q36703061-2C4231CD-BC5E-406A-AF9A-D589F4282B8AQ37116814-7C756396-B375-43FD-A02C-E670BA180A01Q37367643-B604A3C6-13C5-4E89-BB1A-CCE095CB4D10Q37410460-C3AD2880-C845-4970-B2C9-0530458F6488Q37727171-76A78F28-1CC8-473A-986A-D330B29700B4Q37747381-9CF34F33-6A47-44B3-85BE-4DBE49FC1D1DQ38010784-B39B67B3-2DFF-48FD-A49A-3DEAF0B661FFQ38199663-70F2AE6A-1627-4191-9ADD-A05559FB20B8Q38842229-7E59CF65-436C-4DDC-BF43-C882FD2EA3C0Q39993687-3DE1B1F9-E79C-4333-A715-2C46745B2792Q42789542-2DA25E88-AE13-4D58-B860-7C49BB6F7F51Q43203230-7FB32CF7-C934-4E80-944C-E0F1FBEA168CQ43505908-7082539A-DF15-44FD-9C29-2167D9E6651DQ44066133-9C41EAF9-730A-4CD2-B296-8FC5951C2848Q51941776-D52F170D-ED48-4D9C-91B2-3B071236F094
P2860
Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Antimicrobial susceptibility o ...... part of the PROTEKT US study.
@en
Antimicrobial susceptibility o ...... part of the PROTEKT US study.
@nl
type
label
Antimicrobial susceptibility o ...... part of the PROTEKT US study.
@en
Antimicrobial susceptibility o ...... part of the PROTEKT US study.
@nl
prefLabel
Antimicrobial susceptibility o ...... part of the PROTEKT US study.
@en
Antimicrobial susceptibility o ...... part of the PROTEKT US study.
@nl
P356
P1476
Antimicrobial susceptibility o ...... part of the PROTEKT US study.
@en
P2093
Michael J Rybak
Steven D Brown
P356
10.1093/JAC/DKH313
P407
P478
54 Suppl 1
P577
2004-08-01T00:00:00Z